Inclusion Criteria:

        Eligibility is determined priori to leukapheresis. Patients must satisfy the following
        criteria to be enrolled in this study:

          1. Signed Informed Consent Form

          2. Male or female patients who are 18-75 years of age

          3. Histologically confirmed ALCL, PTCL- NOS, ENKTCL nasal type, DLBCL-NOS and PMBCL

          4. Relapsed or refractory CD30-positive NHL who have failed all available standards of
             therapy. Patients may or may not have received an autologous or allogeneic HSCT
             CD30-positive tumor

          5. At least 1 measurable lesion according to the Lugano Classification

          6. ECOG PS of 0 to 1 or equivalent Karnofsky PS Anticipated life expectancy >12 weeks

        Exclusion Criteria:

          1. CNS involvement by malignancy

          2. Inadequate laboratory abnormalities at screening:

             Hgb ≤ 8.0 g/dL Total bilirubin > 1.5 x ULN (>2 x ULN for patients with Gilbert's
             syndrome) AST and ALT ≥ 5 x ULN CrCL ≤ 45 mL/min (as measured by Cockcroft-Gault
             equation) ANC ≤ 1000/uL Platelets ≤75,000/uL PR or INR >1.5 x ULN aPTT> 1.5 x ULN

          3. Active uncontrolled bleeding or a known bleeding diathesis

          4. Inadequate pulmonary function defined as pulse oximetry < 90% on room air

          5. Ongoing treatment with immunosuppressive drugs including calcineurin inhibitions,
             TNFalpha, mTOR, etc or chronic systemic corticosteroids (>10 mg/day prednisone or
             equivalent for >48 hours)

          6. Received prior therapy of:

             Anti-CD30 Ab based therapy within the previous 8 weeks Previous CD30.CAR-T
             investigational product Bi-specific CD30 Ab within the previous 8 weeks Allogenic HSCT
             in the last 180 days Autologous HSCT within 90 days

          7. Active GVHD requiring immune suppression regardless of grade

          8. HIV positive

          9. Active HBV and/or HCV